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Abstract
Background: The Sonic hedgehog (Shh) signaling pathway plays an important role in cerebellar development, and
mutations leading to hyperactive Shh signaling have been associated with certain forms of medulloblastoma, a
common form of pediatric brain cancer. While the fundamentals of this pathway are known, the molecular targets
contributing to Shh-mediated proliferation and transformation are still poorly understood. Na,K-ATPase is a
ubiquitous enzyme that maintains intracellular ion homeostasis and functions as a signaling scaffold and a cell
adhesion molecule. Changes in Na,K-ATPase function and subunit expression have been reported in several cancers
and loss of the β1-subunit has been associated with a poorly differentiated phenotype in carcinoma but its role in
medulloblastoma progression is not known.
Methods: Human medulloblastoma cell lines and primary cultures of cerebellar granule cell precursors (CGP) were
used to determine whether Shh regulates Na,K-ATPase expression. Smo/Smo medulloblastoma were used to assess
the Na,K-ATPase levels in vivo. Na,K-ATPase β1-subunit was knocked down in DAOY cells to test its role in
medulloblastoma cell proliferation and tumorigenicity.
Results: Na,K-ATPase β1-subunit levels increased with differentiation in normal CGP cells. Activation of Shh
signaling resulted in reduced β1-subunit mRNA and protein levels and was mimicked by overexpression of Gli1and
Bmi1, both members of the Shh signaling cascade; overexpression of Bmi1 reduced β1-subunit promoter activity. In
human medulloblastoma cells, low β1-subunit levels were associated with increased cell proliferation and in vivo
tumorigenesis.
Conclusions: Na,K-ATPase β1-subunit is a target of the Shh signaling pathway and loss of β1-subunit expression
may contribute to tumor development and progression not only in carcinoma but also in medulloblastoma, a
tumor of neuronal origin.
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Background
The Sonic hedgehog (Shh) signaling pathway is critical
for patterning, proliferation, and differentiation in em-
bryonic development. Aberrant activation of Shh signal-
ing has been associated with tumorigenesis in various
malignancies [1] including medulloblastoma, a pediatric
brain cancer of the cerebellum [2]. Medulloblastoma is
divided into four biologically different subsets of tumors
defined as Wnt, Shh, Group 3 and Group 4 that have
distinct genetic profiles, pathway signatures, and clinico-
pathological properties [3, 4]. Aberrant activation of Shh
signaling has been implicated in about one third of
medulloblastoma [5, 6]. Tumors of this group are thought
to originate from cerebellar granule cell precursor (CGP)
cells that are located in the external granule layer (EGL) of
the cerebellum, a germinal zone harboring actively pro-
liferating progenitor cells [7, 8]. A tightly regulated switch
to the post-mitotic stage correlates with differentiation
and inward migration of the granule neurons to form the
internal granule layer (IGL). Disruption of the spatio-
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temporal dynamics of CGP proliferation in the EGL, cell
cycle exit, formation of parallel fibers and migration into
the IGL are thought to play a role in medulloblastoma
development [7, 8]. However, factors that regulate these
dynamics are poorly characterized.
Shh is a secreted protein released from Purkinje cells,
being responsible for cerebellar patterning, polarity and
development [2] and is a potent mitogen for CGPs [9].
In general, the Shh pathway is inactive in the absence of
ligand. The transmembrane receptor Patched 1 (Ptch1)
inhibits the activity of the Smoothened (Smo) receptor.
The transcription factor Gli is prevented from entering
the nucleus through interactions with cytoplasmic pro-
teins like Suppressor of fused homolog (Sufu) and tran-
scriptional activation of Shh target genes is repressed
[1]. Activation of the pathway is initiated through Shh
ligand binding to Ptch1 resulting in de-repression of
Smo. This activates a cascade leading to the transloca-
tion of the active form of Gli to the nucleus to activate
gene expression. In medulloblastoma, activating muta-
tions in three Shh pathway components, Ptch1, Smo,
and Sufu, have been identified [10, 11]. Target genes of
the Shh pathway include polycomb group proteins that
are transcription regulatory proteins that form protein
complexes to repress gene transcription [12]. The poly-
comb protein Bmi1 acts downstream of the Shh pathway
to control CGP proliferation [13]. Recent studies showed
that Bmi1 is aberrantly expressed in medulloblastoma
which correlates with the activation of the Shh pathway
[13] and is required for Shh driven medulloblastoma
expansion [14, 15]. The target genes of Bmi1 in medullo-
blastoma are not well-known.
Na,K-ATPase is a ubiquitous membrane protein that
maintains intracellular ion homeostasis and is critical to
the normal function of higher eukaryotic cells, including
neurons. The enzyme consists of a catalytic α-subunit
and a β-subunit and pumps sodium ions out and potas-
sium ions into the cell at the expense of ATP thereby
generating a sodium gradient across the plasma mem-
brane [16, 17]. In recent years, studies from our labora-
tory and other groups have established additional roles
for Na,K-ATPase as a signaling scaffold and a cell adhe-
sion molecule [18–23]. Signaling pathways modulated by
Na,K-ATPase have been linked to cancer development
and progression including cell growth, cell adhesion, and
cell motility. A cell adhesion function has been ascribed
to both the β1 and β2 isoforms. Indeed, the β2-subunit
was initially described as adhesion molecule on glia
(AMOG) and mediates neuron-astrocyte adhesion and
neural cell migration [24]. A recent study suggested that
increasing loss of AMOG plays a role in the invasion
pattern in the malignant progression of gliomas [25–27].
We have shown that loss of β1-subunit expression is as-
sociated with a poorly differentiated phenotype found in
carcinoma cells [21, 28–30]. Changes in Na,K-ATPase
function and expression have been reported in various
cancers [31] and may occur at very early stages of
tumorigenesis [32, 33], suggesting that altered Na,K-
ATPase subunit expression and function may contribute
to tumor development and progression. We previously
found that the β1-subunit is repressed by the transcrip-
tion factor Snail [29] and activation of transforming
growth factor (TGF)-β signaling resulted in reduced β1-
subunit expression in epithelial cells [34, 35]. Whether
activation of Shh signaling regulates β1-subunit levels is
not known.
In this study, we analyzed the expression of Na,K-
ATPase subunits in medulloblastoma tumors of Smo/
Smo mice, a transgenic medulloblastoma mouse model
with aberrant activation of Shh signaling [36]. The levels
of the β1-subunit of Na,K-ATPase were drastically re-
duced in medulloblastoma tumors when compared to
cerebellum of wild-type mice and activation of Shh signal-
ing repressed the β1-subunit expression in differentiating
primary CGP cultures. Overexpression of Gli1 and Bmi1,
both downstream effectors of Shh signaling, resulted in
reduced β1-subunit mRNA and protein expression. Fur-
thermore, shRNA-mediated knockdown of the β1-subunit
in a human medulloblastoma cell line increased cell prolif-
eration and tumorigenicity in xenografts in immunocom-
promised mice suggesting that loss of β1-subunit may
contribute to medulloblastoma progression.
Results
Reduced expression of Na,K-ATPase β1-subunit in
medulloblastoma tumors
We previously found that the Na,K-ATPase β1-subunit
expression correlated with differentiation, being high in
well differentiated epithelial cells and low in poorly dif-
ferentiated cancer cells [21, 28–30]. However, it is not
known whether a similar correlation exists in neuronal
tumors. Since normal cerebellar granule cells express
high levels of the β1 isoform [37], we first compared the
β1-subunit levels in normal cerebella and medulloblas-
toma tumors from Smo/Smo mice. Smo/Smo mice are a
transgenic medulloblastoma mouse model with expres-
sion of a constitutively activated form of the Smo gene
in CGP cells and form medulloblastoma tumors at a
high incidence and early onset [36]. Immunoblotting
revealed drastically reduced β1-subunit levels in medul-
loblastoma tumors as compared to normal cerebellum of
age-matched wildtype C57BL/6 mice (Fig. 1a). Consist-
ent with the reduced β1-subunit expression, β1-subunit
mRNA levels in tumors were only about 20 % of the
levels of normal cerebellum (Fig. 1b). Protein and mRNA
levels of the α1-subunit, the major isoform in CGP cells
[37] were also reduced. Furthermore, the β1-subunit pro-
tein (Fig. 1c) and mRNA (Fig. 1d) levels increased with
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time in differentiating primary cultures of CGP cells iso-
lated from normal cerebella suggesting that the β1-subunit
levels increase with the differentiation of CGP cells.
Reduced Na,K-ATPase β1-subunit expression increases cell
proliferation and tumorigenicity
To test whether loss of β1-subunit expression affects
medulloblastoma progression, we used an RNA interfer-
ence approach to knockdown β1-subunit in the human
medulloblastoma cell line DAOY. From two independent
transfections and selections we obtained two clones of
β1-subunit knockdown cells with a 65 % (Sh-NaKβ-cl1)
and 81 % (Sh-NaKβ-cl2) reduction in β1-subunit expres-
sion compared to the respective control cells (ShV-cl1 and
ShV-cl2) that were transfected and selected in parallel with
each clone (Fig. 2a, b). The α1-subunit levels were com-
parable in control and knockdown cells, which is likely
due to the compensatory increase of the β2-isoform in
knockdown cells (Fig. 2c). Interestingly, cells from both
β1-subunit knockdown clones proliferated 1.6 +/− 0.05
(cl1) and 1.5 (cl2) times faster than the respective control
cells by day 4 (Fig. 2d). The increase in proliferation in β1-
subunit knockdown cells was further confirmed by BrdU
uptake experiments (Fig. 2e).
Furthermore, in subcutaneous tumor xenografts in im-
munocompromised mice there was a significant difference
in the overall mean volume between the group of vector
control (ShV-cl1) and β1-subunit knockdown (Sh-NaKβ-
cl1) (Fig. 3a). The overall mean volume (SE) was 0.236
(0.112) cm3 and 0.563 (0.112) cm3 in ShV-cl1 and Sh-
NaKβ-cl1, respectively. The difference in the mean (SE)
was 0.327 (0.158) cm3, p = 0.049. The changes between
the groups over time were significantly different (p-value
(for Time*Group) <0.001) (n = 12). Week-wise, the mean
differences between two groups were highly significant
after week 8. A survival analysis estimated the risk of
dying in Sh-NaKβ-cl1 as 4.8 times higher compared to the
risk of dying in ShV-cl1 and a Kaplan Meier survival
function was used to compare the probability of surviving
between two groups (Fig. 3b). qPCR (Fig. 3c) and im-
munoblot (Fig. 3d) analysis from tumors obtained at
termination of the study at 12 weeks, confirmed that the
β1-subunit knockdown had been maintained in vivo. In
addition, tumors from β1-subunit knockdown cells had
higher cyclin D1 levels (Fig. 3e). At the same time, cyclin
D1 expression itself did not result in reduced β1-subunit
levels (data not shown). Thus, reduced β1-subunit ex-
pression in medulloblastoma cells is associated with
increased proliferation and tumorigenicity, suggesting
that loss of the β1-subunit may contribute to medulloblas-
toma progression rather than being a byproduct of in-
creased proliferation.
Fig. 1 Na,K-ATPase subunits in medulloblastoma and CGP cells. a. Na,K-ATPase α1- and β1-subunit expression in cerebellum from 6 month old WT
C57BL6/J mice (WT) and tumors from age-matched Smo/Smo mice. An immunoblot for GAPDH confirmed equal loading of protein. b. Na,K-ATPase
α1-subunit and β1-subunit mRNA levels in WT and medulloblastoma cerebellum normalized to beta-2 microglobulin. For both α1- and β1-subunit the
difference between WT and medulloblastoma cerebellum is statistically significant (p < 0.005) (n = 3). c. Primary CGP cells isolated from C57BL/6 J mice
were cultured in vitro for 3, 6, 9 and 12 days and then lysed for immunoblotting with indicated antibodies. α-tubulin was used as a loading control.
d. mRNA levels of α1- and β1-subunit during differentiation of CGP cells cultured in vitro and normalized to beta-2 microglobulin
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Activation of Shh signaling suppresses the Na,K-ATPase
β1-subunit
Since Shh signaling is a major pathway affected in me-
dulloblastoma and Smo/Smo mice express constitutively
active Smo, we next tested whether activation of Shh
affects the β1-subunit levels. CGP cells isolated from nor-
mal cerebellum were differentiated in culture or treated
with the Smo agonist SAG to induce cell proliferation
(Fig. 4a). Indeed, SAG treatment prevented the increase in
β1-subunit expression (Fig. 4b) that was found in control
CGP cells (Figs. 1c, 4b). Similar to Smo/Smo tumors,
β1-subunit downregulation upon Shh activation occurred
at the transcriptional level as SAG treatment not only in-
creased Gli1 levels but also reduced β1-subunit mRNA
Fig. 2 Knockdown of Na,K-ATPase β1-subunit in medulloblastoma cells increases cell proliferation. a. Na,K-ATPase β1-subunit protein levels in two
independent clones of shRNA-mediated β1-subunit knockdown in DAOY cells (Sh-NaKβ-cl1 and cl2). ShV-cl1 and cl2 are respective scrambled
shRNA transfected control clones that were obtained in parallel with each of the two independent selections. b. Quantification of β1-subunit
levels in knockdown cells relative to the levels in the respective control clones from three (Sh-NaKβ-cl1 and ShV-cl1; p < 0.005) or two (Sh-NaKβ-cl2
and ShV-cl2) immunoblots. c. Na,K-ATPase β2-isoform and α1-subunit expression in β1-subunit knockdown cells. d. Cell proliferation of β1-subunit
knockdown clones expressed as fold change relative to cell number at day 0. The differences in fold change between ShV-cl 1 and Sh-NaKβ-cl 1 were
statistically significant at days 2, 3, and 4 (p < 0.05). e. BrdU uptake in β1-subunit knockdown cells. There was a significant difference in percent BrdU
positive cells between cell lines (p < 0.005, two way ANOVA). The difference in percent BrdU positive cells was significant starting on day
3 (* = p < 0.05)
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levels to 34 % of that of control cells (Fig. 4c). Interest-
ingly, the β1-subunit mRNA level in SAG-treated cells was
similar to that of primary cultures of tumor cells from
Smo/Smo mice (Fig. 4c). Furthermore, in ONS-76 and
DAOY cells SAG-treatment reduced the β1-subunit levels
by about 40 % as compared to control cells and clearly
decreased mRNA levels (Fig. 4d-f). However, compared to
primary CGP cultures, SAG-treatment of DAOY cells did
not reduce the β1-subunit as drastically. Probably these
cells were less sensitive to SAG-treatment which is con-
sistent with the lower levels of Gli1 observed in these cells.
To further investigate whether activation of Shh signaling
results in reduced β1-subunit levels, we transiently trans-
fected HEK293T cells with EGFP-tagged Gli1. As com-
pared to EGFP vector control cells, the β1-subunit in Gli1
overexpressing cells was reduced by 30 % (Fig. 4g). Thus,
activation of Shh signaling represses β1-subunit mRNA
levels and protein expression.
Bmi1 represses β1-subunit expression
Gli proteins can function as transcriptional activators
and repressors, but Gli1 is mostly known as a transcrip-
tional activator. One of the target genes of Gli1 is the
polycomb protein Bmi1, a transcriptional suppressor
that is upregulated upon Shh activation in medullo-
blastoma [15]. Consistent with these studies we found
drastically increased Bmi1 protein (Fig. 5a) and mRNA
(Fig. 5b) levels in Smo/Smo medulloblastoma when
compared to normal cerebellum. Thus, Bmi1 inversely
correlated with β1-subunit protein and mRNA levels in
these tumors (Fig. 5a, b). In CGP cells, Bmi1 protein
(Fig. 5c) and mRNA (Fig. 5d) levels decreased with in-
creasing time in culture while β1-subunit mRNA levels in-
creased (Fig. 5d). In SAG-treated CGP cells Bmi1 levels
increased with time while SAG prevented the increase in
β1-subunit that was observed in control cells (Fig. 5e).
This inverse relationship of Bmi1 and β1-subunit levels in
Fig. 3 Tumor xenografts of Na,K-ATPase β1-subunit knockdown cells. a. Tumor volume of subcutaneous xenograft tumors injected into
immunocompromised mice (n = 12). The difference in the overall mean volume between the group of ShV-cl1 and Sh-NaKβ-cl1 tumors was
significant (p < 0.05, determined using a mixed effect model with AR(1) correlation structure). b. Kaplan-Meier survival curve of mice with ShV-cl1
(ShV) and Sh-NaKβ-cl1 (Sh-NaK-beta) tumors (p < 0.05). c. Average β1-subunit mRNA levels from three representative tumors of ShV-cl1 and
Sh-NaKβ-cl1 cells normalized to beta-2 microglobulin. The difference in mRNA expression was significant (** = p < 0.005). d. β1-subunit protein
levels in xenograft tumors shown in c. An immunoblot for tubulin served as loading control. e. Cyclin D1 levels in xenograft tumors shown in
c. An immunoblot for tubulin served as loading control
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Fig. 4 Activation of Shh signaling prevents Na,K-ATPase β1-subunit upregulation during CGP differentiation. a. Phase contrast images showing
proliferation of CGP cells after six days of treatment with 0.1 μM SAG. Scale bar, 100 μm. b. In vitro cultured CGP cells were incubated with either
DMSO or 0.1 μM SAG for the indicated period of time and β1-subunit levels were determined by immunoblotting. α-tubulin was used to ensure
equal loading. c. β1-subunit mRNA levels in CGP cells cultured from WT mice. mRNA levels are from CGP cells treated with DMSO or 0.1 μM SAG
for seven days, and CGP cells cultured from Smo/Smo mice. The mRNA levels were normalized to control cells treated with DMSO. The differences in
β1-subunit mRNA levels between DMSO and SAG treated and DMSO and Smo/Smo CGP cells were significant (** = p < 0.005). d. Immunoblots for
β1-subunit and Gli1 in ONS-76 cells treated for 48 h with 0.1 μM SAG. α-tubulin served as loading control. e. Immunoblots for β1-subunit and Gli1 in
DAOY cells treated for 48 h with 0.1 μM SAG. α-tubulin served as loading control. The β1-subunit level relative to the level of α-tubulin in SAG-treated
cells was reduced to 60 % of the β1-subunit level in DMSO-treated control cells. f. β1-subunit and Gli1 mRNA levels in DAOY cells treated for 2 h with
0.1 μM SAG. β-actin was used as the endogenous control. The difference between the mRNA levels of β1-subunit and Gli1 was significant
(* = p < 0.05). g. β1-subunit levels in Gli1 overexpressing cells. 293 T cells were transfected with pEGFPC1-Gli1 or pEGFPC1 vector as control
for 72 h. Immunoblots for β1-subunit and Gli1 are shown. α-tubulin served as loading control. The β1-subunit level relative to the level of α-tubulin in
Gli-transfected cells was only 70 % of the β1-subunit level in vector only-transfected cells
Lee et al. Molecular Cancer  (2015) 14:159 Page 6 of 13
Smo/Smo tumors and in CGP cells suggested that Shh
signaling-induced β1-subunit repression might be medi-
ated by Bmi1. To determine whether Bmi1 represses the
β1-subunit, we transiently expressed Bmi1 in 293 T cells
and found that the β1-subunit protein levels decreased
with increasing levels of Bmi1 (Fig. 6a). Furthermore, to
test whether Bmi1 transcriptionally represses the β1-sub-
unit promoter, we transiently co-transfected Bmi1 with a
luciferase reporter construct under the control of the hu-
man β1-subunit promoter (Hβ1-1141-Luc) [38] in 293 T
cells. Bmi1 expression significantly reduced the β1-subunit
promoter activity to 85.7 ± 2.3 % of that of control vector
transfected cells (Fig. 6b). To further confirm that Bmi1
inhibits β1-subunit transcription by controlling its pro-
moter activity, we co-transfected 293 T cells with human
Bmi1 shRNA and Hβ1-1141-Luc constructs. Silencing of
Bmi1 increased β1-subunit promoter activity in a dose
dependent manner (Fig. 6c). Together, these data show
that Bmi1 represses β1-subunit promoter activity and
down-regulates its expression.
Discussion
In this study, we provide evidence that the β1-subunit of
Na,K-ATPase is a target of Shh signaling in vitro and in
vivo and that its expression is reduced in medulloblastoma
tumors. We show that the Na,K-ATPase β1-subunit levels
are reduced in mouse medulloblastoma from Smo/Smo
mice with constitutive activation of the Shh signaling
pathway. We further demonstrate that in primary cultures
of CGPs from wild-type mice the β1-subunit levels in-
crease with differentiation which can be prevented by acti-
vation of Shh-signaling. Downregulation of the β1-subunit
could be mimicked by expressing the transcription factors
Gli1, a well-known member of the Shh signaling cascade,
and Bmi1, a polycomb protein that can be induced by Shh/
Gli1 in medulloblastoma [15]. Furthermore, in human me-
dulloblastoma cells, low β1-subunit levels were associated
with increased cell proliferation and in vivo tumorigenesis.
Studies from our and other groups have previously shown
that Na,K-ATPase β1-subunit levels are low in undifferen-
tiated carcinoma cells derived from epithelia [21, 28–31].
Using primary cultures of normal cCGPs, human medullo-
blastoma cell lines and a transgenic medulloblastoma
mouse model, we now provide evidence that loss of β1-
subunit expression also occurs in brain tumor cells and
suggest that altered β1-subunit expression and function
may contribute to tumor development and progression not
only in carcinoma but also in tumors of neuronal origin.
Fig. 5 Inverse relationship between Bmi1 and Na,K-ATPase β1-subunit levels in medulloblastoma and CGP cells. a. Protein extracts obtained from
four Smo/Smo medulloblastoma and cerebellum of four wild type mice were immunoblotted with the indicated antibodies. α-tubulin was used
as loading control. b. mRNA levels of Bmi1 and β1-subunit in medulloblastoma and cerebellum as determined by qRT-PCR. c. Protein levels of
Bmi1 in differentiating CGP cells. GAPDH was used to ensure equal loading. d. mRNA levels of Bmi1 and β1-subunit in CGP cells differentiating in
vitro. The difference in β1-subunit mRNA expression was significant during CGP differentiation (** = p < 0.001, one way ANOVA), while the
difference in Bmi1 expression was not significant (one way ANOVA). e. CGP cells grown in vitro were exposed to either DMSO or 0.1 μM SAG for
indicated time points and the lysates were immunoblotted with the indicated antibodies. GAPDH served as loading control
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It is well established that the Na,K-ATPase pump
function is essential to maintain intracellular ion homeo-
stasis and cell volume and to fulfill more tissue-specific
functions like transepithelial ion and nutrient transport
in epithelia or maintaining the membrane resting poten-
tial in excitable tissues. Na,K-ATPase also serves as a
signaling scaffold and the β-subunit functions as a cell
adhesion molecule [18–23]. The pump function of the
α-subunit and the adhesion function of the β1-subunit
are crucial for the formation and maintenance of tight
junctions and the polarized phenotype of epithelial cells
[21, 31, 39]. This role appears to be conserved as Na,K-
ATPase function and β1-subunit expression are not only
required for blastocyst formation in mouse embryos and
tight junction formation in mammalian cells but also for
the formation of septate junctions, the tight junction
homolog in Drosophila, and myocardial cell junctions in
zebrafish [31]. Epithelial cells exhibit a polarized distri-
bution of proteins and lipids in the apical and basolateral
plasma membrane domains. Similarly, neuronal cells are
highly polarized cells with an axon and a somatodendri-
tic domain. Many membrane proteins such as adhesion
Fig. 6 Bmi1 represses Na,K-ATPase β1-subunit. a. β1-subunit expression in 293 T cells transiently transfected with increasing amounts of pEGFPC1
or pEGFPC1-Bmi1. Immunoblots for β1-subunit, GFP, and Bmi1 are shown. α-tubulin serves as the loading control. b. Bmi1 decreased β1-subunit
promoter activity in 293 T cells transfected with pEGFPC1 or pEGFPC1-Bmi1 together with β1-subunit promoter-Luc and Renilla control vector.
48 h after transfection, dual-luciferase assays were performed and Firefly luciferase activity was normalized to the Renilla luciferase signal to
control for transfection efficiency. Data shown are from three experiments (* = p < 0.05). c. Knockdown of Bmi1 increased β1-subunit promoter
activity in 293 T cells. 293 T cells were co-transfected with empty vector or human Bmi1 shRNA construct together with β1-subunit promoter-Luc
and Renilla control vector. 48 h after transfection, dual-luciferase assays were performed as in b. Data shown are representative of two independent
experiments (** = p < 0.01) d. Schematic model depicting Shh-mediated repression of Na,K-ATPase β1-subunit resulting in increased proliferation
and tumorigenicity
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molecules, growth factor receptors, and ion channels are
asymmetrically distributed into these two distinct cellu-
lar compartments that are separated by the axon initial
segment (AIS). The AIS is enriched in voltage-gated ion
channels, cell adhesion molecules and cytoskeletal scaf-
folding proteins and acts as a diffusion barrier [40].
Interestingly, recent studies showed that an increase in
Na,K-ATPase α1-subunit preceded other proteins in the
AIS and that abnormal α1-subunit levels resulted in
altered structure and function of the AIS [41]. As cells
from the central nervous system arise from neuroepithe-
lium, it is believed that similar events in epithelial and
neuronal cells shape neuronal differentiation [42]. Thus,
it is possible that Na,K-ATPase function and expression
are not only crucial for epithelial differentiation but also
for the polarization of neuronal cells.
We have shown that loss of β1-subunit expression in
normal epithelial cells is associated with epithelial-
mesenchymal transition (EMT) [34, 35], a key step to-
wards progression to a malignant phenotype in cancer.
During EMT epithelial cells undergo a developmental
switch resulting in decreased adhesion, loss of cell polarity
and increased proliferation and invasiveness, a patho-
logical process in cancer and a physiological process dur-
ing normal development. During cerebellar development,
neuronal precursors, and in particular CGPs, appear to
undergo a switch similar to EMT [43]. In rodents, prolif-
erating CGPs differentiate into granule neurons in the
EGL and then migrate radially from the EGL into the in-
ternal granule layer (IGL) during postnatal maturation.
While in the EGL, CGPs proceed through an unpolarized
state with limited contact with neighboring neurons be-
fore forming neuron-glial junctions in order to move into
the IGL. This process in many ways resembles EMT and
the mesenchymal-epithelial transitions (MET) found in
epithelial tissue formation during development. We earlier
found that the β1-subunit expression increased during
epithelial polarization (data not shown), and that the
β1-subunit acts synergistically with the cell adhesion
molecule E-cadherin to induce a polarized, epithelial
phenotype [21]. We now show that the β1-subunit
levels increase in primary cultures of CGP cells with
increasing differentiation (Fig. 1c) and it is possible that in
these cells the β1-subunit cooperates with neuronal cell
adhesion molecules to induce differentiation as they
undergo MET. We previously also provided evidence that
the β1-subunit homodimerizes with the β1-subunit of ad-
jacent cells [44] which was required to suppress cell prolif-
eration in response to contact inhibition in renal epithelial
cells [45]. Thus, it is also possible that in neuronal cells
the β1-subunit plays a similar role and either may suppress
proliferation in the EGL through contact inhibition or
tether the CGP cells at the IGL to terminate migration.
Studies are in progress to determine whether ablation of
the β1-subunit affects the differentiation/migration of
CGP cells during cerebellar development.
We have previously shown that Snail, a master regulator
of EMT, binds to a non-canonical E-box in the β1-subunit
promoter and transcriptionally suppresses the β1-subunit
[29]. It has also been reported that activation of Shh sig-
naling induces Snail1 in CGP cells [46]. Nevertheless, the
Snail1 levels were similar in wild-type cerebella and in me-
dulloblastoma tumors of Smo/Smo mice (Fig. 5a) suggest-
ing that other transcription factors may play a primary
role in Shh-induced downregulation of the β1-subunit.
We previously made a similar finding in TGF-β induced
EMT in human retinal pigment epithelial cells. While
Snail is one of the major transcription factors induced by
TGF-β signaling we did not find Snail to downregulate the
β1-subunit in ARPE19 cells despite reduced β1-subunit
levels in response to TGF-β treatment [35]. Rather, sup-
pression of the β1-subunit was mediated by the transcrip-
tion factors hypoxia-inducible factor (HIF-1α) and Smad3.
While we found slightly increased Smad3 and Smad4
levels in Smo/Smo medulloblastoma as compared to cere-
bellum from wild-type mice (Fig. 5a), TGF-β treatment of
DAOY cells did not result in reduced β1-subunit promoter
activity despite increased levels of phosphorylated Smad3
indicating activation of the TGF-β signaling pathway in
these cells (data not shown). It has previously been shown
that activation of Shh or overexpression of Gli1 induced
Bmi1 expression and knockdown of Bmi1 reduced medul-
loblastoma growth [14, 15, 47, 48]. We now found an
inverse relationship between Bmi1 and β1-subunit levels
in CGP cells and Smo/Smo medulloblastoma and that
Bmi1 suppressed the promoter activity of the β1-subunit
identifying Bmi1 as a novel transcriptional regulator of the
β1-subunit. Analysis of two publicly available datasets,
GSE3526 [49] and GSE37418 [50], revealed that compared
to normal cerebellum, human medulloblastoma tumors
showed decreased ATP1B1 and increased Bmi1 levels
across all subgroups with a p-value of 4.1e-07 (ATP1B1)
and 9.2e-28 (Bmi1). However, when the correlation of the
ATP1B1 and Bmi1 levels was tested between the sub-
groups we found no significant correlation between these
two genes in the individual groups (data not shown). Des-
pite this lack of significance, these findings are consistent
with previous reports analyzing the transcription expres-
sion profiles of DAOY cells with shRNA mediated knock-
down of Bmi1 that found increased β1-subunit levels
when Bmi1 was reduced [47]. While Bmi1 overexpression
has been suggested as a mechanism in the pathogenesis of
medulloblastoma, Bmi1 overexpression itself did not in-
duce medulloblastoma but rather appeared to enhance
tumor cell survival and proliferation [51]. Furthermore,
Bmi1 was found to control medulloblastoma cell invasion,
cell adhesion and motility [52]. We have previously shown
that low β1-subunit levels are associated with decreased
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cell adhesion and increased invasion, motility and tumori-
genesis of renal cell carcinoma cells [18, 21, 44, 45, 53].
We now show that in medulloblastoma cells decreased
β1-subunit levels are associated with increased prolifera-
tion and tumorigenesis and suggest that at least in part
Bmi1 mediates its effects on tumor progression through
repression of the β1-subunit of Na,K-ATPase.
Conclusions
Medulloblastoma is the most common pediatric brain
tumor. It has a worse prognosis than many other pediatric
cancers and understanding the molecular factors that con-
tribute to medulloblastoma progression is a prerequisite
for developing novel therapeutic approaches. It is now
well accepted that Na,K-ATPase forms a macromolecular
complex with cell adhesion molecules and signaling pro-
teins and increasing evidence suggest that it is involved in
the regulation of cell proliferation and migration in epi-
thelial cells. We and others have also shown that loss of
β1-subunit expression is associated with a poorly differen-
tiated phenotype of carcinoma cells. We now report that
reduced β1-subunit levels are associated with increased
proliferation and invasiveness of medulloblastoma and
identified Bmi1 as a novel transcriptional regulator of the
β1-subunit while at the same time known regulators that
play a major role in EMT such as Snail and TGF-β ap-
peared to be less important. Thus, while we can learn
significantly from the wealth of knowledge about signaling
pathways in epithelial cancers, it appears that tumor spe-
cific regulators in medulloblastoma remain. On the other
hand identification of Shh as a regulator of β1-subunit in
cerebellar granule cells may open up the door for studies
on the more recently identified roles of Shh in EMT and
epithelial cancers.
Methods
Cell culture and transfection
Human medulloblastoma DAOY cells obtained from
American Type Culture Collection (ATCC, Manassas, VA)
were cultured in Minimum Essential Media (MEM) sup-
plemented with 10 % fetal bovine serum and penicillin-
streptomycin-glutamine at 37 °C and 5 % CO2. ONS-76
cells were kindly provided by Dr. Michael Taylor. For
treatment with the Smo agonist SAG (Santa Cruz,
Biotechnology, Dallas, TX), DAOY cells were serum-
starved overnight and then treated with 0.1 μM SAG
for indicated times.
293 T cells were cultured in Dulbecco’s modified Eagle
Medium (DMEM) supplemented with 10 % fetal bovine
serum and penicillin-streptomycin-glutamine at 37 °C and
5 % CO2. 293 T cells were transiently transfected with
same amounts of control vector or human Gli1 or human
Bmi1 expression constructs. Two or three days after trans-
fection, cells were collected for further experiments. For
human Gli1 and Bmi1 constructs the coding region was
obtained by PCR from cDNA using the following primers:
Gli forward, 5′-ACGAAGATCTATGTTCAACTCGATG
ACCCC-3′; Gli reverse, 5′-GAGCGTCGACTTAGGCA
CTAGAGTTGAGGAATTCT-3′; Bmi1 forward, 5′-AC
GAAGATCTATGCATCGAACAACGAGAATCAAGAT
C-3′; Bmi1 reverse, 5′-GAGCGTCGAC TCAACCAGA
AGAAGTTGCTGATGACC-3′. The inserts were cloned
into pEGFPC1 using the BglII and SalI restriction sites.
The insert was confirmed by sequencing.
For knockdown studies, the shRNA sequence (5′-
GTGATGCTGCTCACCATCA-3′) that targets human
Na,K-ATPase β1-subunit was cloned into the pSilencer
5.1 vector (Ambion, Austin, TX) as described earlier
[34]. Na,K-ATPase β1-shRNA transfection of DAOY cells
was performed using either the Amaxa Nucleofector
(Lonza, Walkersville, MD) (clone 1) or Lipofectamine
2000 (Life Technologies, Grand Island, NY) (clone 2)
and single clones were selected after treatment with
10 μg/ml of puromycin (Sigma-Aldrich Co. LLC, St.
Louis, MO). Knockdown of the β1-subunit was confirmed
by immunoblotting. Representative clones transfected
with the scrambled sequence vector (5′-ACAGAATTG
AATCATGCCGTC-3′) were selected in parallel. Two
matched sets of β1-subunit knockdown and vector control
cells were obtained from two independent transfections/
selections. The shRNA sequence (5′-GACCAGACCACT
ACTGAAT-3′) that targets human Bmi1 was cloned into
the pSIREN-DNR-DsRed-Express vector (Clontech).
Primary culture of CGP cells
Cerebellum dissected from mice of postnatal days 4–6
were dissociated into single cells using the Papain Dis-
sociation System kit (Worthington Biochemical Corp,
Freehold, NJ). After filtering through a nylon mesh, the
cell suspension was plated twice to remove astroglial
cells and fibroblasts. CGPs were cultured in poly-D-lysine
coated dishes in Neurobasal medium supplemented with
0.25 mM KCl and B27.
RNA extraction and qPCR
Total RNA was extracted from cerebellum of wildtype
C57BL/6 mice, medulloblastoma tumors of Smo/Smo
mice and in vitro cultured CGP cells or DAOY cells
using TRIzol reagent (Life Technologies, Carlsbad, CA).
Total RNA was treated with TURBO DNA freeTM Kit
(Ambion, Life Technologies). 1 μg of RNA was used to
produce cDNA using the iScript cDNA Synthesis kit
(Bio-Rad, Hercules, CA). Quantitative PCR analysis was
performed with a SYBR Green PCR master mix (Applied
Biosystems, Foster City, CA) using an ABI Prism 7900
Sequence Detection System (Applied Biosystems).
The following primer sets were used: 5′-ACCAATCT
TACCATGGACACTGAA-3′ (human Na,K-β1 forward);
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5′-CGGTCTTTCTCACTGTACCCAAT-3′ (human Na,K-
β1 reverse); 5′-ACCCGGGGTCTCAAACTG-3' (Gli1
forward); 5′- GGCTGACAGTATAGGCAGAGC-3′ (Gli1
reverse); 5′-AATGTGGCCGAGGACTTTGATTGC-3′
(β-actin forward); and 5′-AGGATGGCAAGGGACTT
CCTGTAA-3′ (β-actin reverse); 5′- TTCTGGTGCTTG
TCTCACTGA-3′ (Beta2 microglobulin forward); 5′- CA
GTATGTTCGGCTTCCCATTC-3′ (Beta2 microglobulin
reverse); 5′- TGATCAGCATGGCCTATGGACAGA-3′
(mouse Na,K-α1 forward); 5′- TGAAAGGGCAGGAA
ACCGTTCTCA-3′ (mouse Na,K-α1 reverse); 5′-GGT
GGCAGTTGGTTTAAGATCC-3′ (mouse Na,K-β1 for-
ward); 5′-GGAATCTGTGTTAATCCTGG-3′ (mouse
Na,K-β1 reverse); 5′-ACGTCATGTATGAAGAGGAAC
CT-3′ (mouse Bmi1 forward); 5′-GCAATGTCCATTAG
CGTGTAGT-3′ (mouse Bmi1 reverse).
Immunoblotting
Tissue or cell extracts were prepared either with a Triton
lysis buffer (20 mM Tris–HCl, pH 7.4), 150 mM NaCl,
1 mM EDTA, 0.1 % Triton X-100, 1 mM sodium ortho-
vanadate supplemented with protease inhibitor cocktails)
or SDS lysis buffer (25 mM Tris–HCl, pH 7.4, 0.5 mM
EDTA, 95 mM NaCl and 2 % SDS). Equal amounts of
protein were separated by SDS-PAGE, transferred to a
nitrocellulose membrane, blocked in 5 % skim milk in
Tris-buffered saline with 0.1 % Tween 20 (TBST), and
incubated overnight with primary antibody diluted in
5 % bovine serum albumin/TBST or 5 % milk/TBST.
HRP-conjugated secondary antibodies and Enhanced
Chemiluminescence Plus to visualize protein bands.
Image J software was used for densitometric analysis of
the immunoblots. The following antibodies were used:
anti-Bmi1 (#5856), anti-Gli1 (#2643), anti-Smad4 (#9515),
anti-Smad3 (#9523), anti-GAPDH (#2118), cyclin D1
(92G2) and anti-α-tubulin (#3873) from Cell Signaling
Technology, anti-GFP (sc-9996) and anti-Na,K-ATPas α1-
subunit (sc-71638) from Santa Cruz Biotechnology, anti-
Na,K-ATPase β1-subunit (HPA012911) from Sigma, and
anti-Snail (ab17732) from Abcam (Cambridge, MA).
Luciferase assays
293 T cells were transfected with 0.1 μg of the human
Na,K-ATPase β1-subunit promoter (Hβ1-1141-Luc) fire-
fly luciferase reporter construct and same amounts of
control vector, human Bmi1 expression construct or
human Bmi1 shRNA construct. To normalize for trans-
fection efficiency, 10 ng pRL-TK Renilla luciferase con-
trol plasmid was added to each transfection. Within the
same experiment, each transfection was performed in
triplicate. Two days after transfection, dual-luciferase
reporter assays were performed using the dual luciferase
assay kit (Promega, Madison, WI). Firefly luciferase activ-
ities were normalized to Renilla luciferase luminescence.
Cell proliferation assay
Proliferation of Na,K-ATPase β1-subunit knockdown
and control cells was measured by cell counting and by
a BrdU incorporation assay. For cell counting, on day 0,
15,000 of both cell types were plated and the cell num-
ber in each well was determined using a hemocytometer
on days 1 through 4. Final counts were averages from 3
different cell counts and values shown are averages from
three independent experiments. For the BrdU incorpor-
ation assay, on day 0, 150,000 cells of both cell types
were plated. On days 1 through 4, cells were labeled
with 30 μM BrdU (Life Technologies) for 2 h and then
harvested for flow cytometry. Cells were stained with an
anti-BrdU Alexa Fluor 488 conjugate antibody (Life Tech-
nologies) and propidium iodide, then analyzed on a BD
Accuri C6 flow cytometer. Values shown are averages
from two independent experiments done in triplicates.
In vivo studies
Female hairless SCID mice (Charles River Laboratories,
Wilmington, MA), 5–6 weeks old, were injected subcuta-
neously with 7 × 106 Na,K-ATPase β1-subunit knockdown
(Sh-NaKβ-cl1) or control (ShV-cl1) DAOY cells with
matrigel as described previously [54] (n = 12). Tumors
were allowed to grow for 3 weeks and then the tumor size
was measured weekly with a caliper. Tumor volumes
were calculated according to the formula short diameter
squared × longest diameter × 0.5. Mice that had tumors
with a longest diameter of 1.7 cm were euthanized. Tu-
mors were harvested, and tumor lysates were prepared in
buffer containing 10 mM Tris–HCl, 150 mM NaCl, 1 mM
EDTA, 0.1 % Triton X-100 supplemented with phos-
phatase and protease inhibitors. All animal studies were
approved by the institutional IACUC committee.
For statistical analysis of tumor growth rates, a mixed
effect model with AR(1) correlation structure was used
to compare the changes in the mean volume between
control (ShV-cl1) and β1-subunit knockdown cells (Sh-
NaKβ-cl1). Variable ‘Volume’ was used the response and
group, time (weeks), and interaction of group and time
(Time*Group) were used as fixed factors. The id of each
mouse was used as random factor to account for the
heterogeneity of individual mice. The last value of the
volume was carried forward for the mice sacrificed be-
fore week 12.
For survival analysis, Cox-regression for proportion
model was used to compare the risk of dying (sacri-
ficing) between two groups and a Kaplan Meier survival
function was used to compare the probability of survival
between two groups.
Statistical analysis
Data are presented as mean ± SD unless otherwise indi-
cated. Differences between means of the two groups
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were analyzed with the use of a two-tailed unpaired
Student’s t-test. When applicable, P values are stated
in the figure legends.
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